Transcode Therapeutics (RNAZ) Operating Expenses (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Operating Expenses came in at $17.8 million in Q1 2026, up 459.89% YoY from $3.2 million in Q1 2025, and up 10.79% on a QoQ basis from $16.0 million in Q4 2025.
Transcode Therapeutics (RNAZ) Operating Expenses (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 7 years of Operating Expenses data on file, last reported at $17.8 million in Q1 2026.
- Quarterly Operating Expenses rose 459.89% year-over-year to $17.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.6 million (up 173.85% YoY) and the FY2025 annual result came in at $28.0 million, up 78.66% from the prior year.
- Operating Expenses improved to $17.8 million in Q1 2026, from $16.0 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $17.8 million in Q1 2026 to a low of $2.2 million in Q3 2024.
- A 5-year average of $5.8 million and a median of $4.9 million in 2023 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses soared 1224.03% — and 2024, when it plunged 59.22%.
- Tracing RNAZ's Operating Expenses over 5 years: stood at $5.5 million in 2022, then declined by 25.44% to $4.1 million in 2023, then grew by 24.28% to $5.1 million in 2024, then soared by 214.72% to $16.0 million in 2025, then rose by 10.79% to $17.8 million in 2026.
- The last three Operating Expenses figures came in at $17.8 million (Q1 2026), $16.0 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | 6.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.76 Mn |
| Dec 31, 2025 | 16.03 Mn |
| Sep 30, 2025 | 4.56 Mn |
| Jun 30, 2025 | 4.22 Mn |
| Mar 31, 2025 | 3.17 Mn |
| Dec 31, 2024 | 5.09 Mn |
| Sep 30, 2024 | 2.17 Mn |
| Jun 30, 2024 | 5.11 Mn |
| Mar 31, 2024 | 3.29 Mn |
| Dec 31, 2023 | 4.10 Mn |
| Sep 30, 2023 | 5.31 Mn |
| Jun 30, 2023 | 5.12 Mn |
| Mar 31, 2023 | 4.89 Mn |
| Dec 31, 2022 | 5.50 Mn |
| Sep 30, 2022 | 4.95 Mn |
| Jun 30, 2022 | 4.71 Mn |
| Mar 31, 2022 | 3.48 Mn |
| Dec 31, 2021 | 2.99 Mn |
| Sep 30, 2021 | 2.36 Mn |
| Jun 30, 2021 | 355,528.00 |